Cite

HARVARD Citation

    Liu, B. et al. (n.d.). 207TiPA phase I/II trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies. Annals of oncology. p. . [Online]. 
  
Back to record